u/noor_ivaturi

keep every form, every date, every reference number

What does the tolerability table in that paper actually say?

The tolerability tables were more informative than the headline numbers, which is usually the case and never how it gets summarised.

Which receptor family are you attributing that effect to?

Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.

Stopped at a low step because there was no reason to go further and no data to tell me what further would do.

Which province?

a lot of the confident posting here is extrapolation

do not assume the dosing intuitions from the GLP-1 boards transfer

Careful, that is a nutrition prescription aimed at another member and this board does not do those.

Employer-sponsored plans have their own criteria and appeal processes, independent of the provincial formulary. Which one applies determines everything about the route.

Phase 2 estimates effect and finds a dose range. Phase 3 estimates it precisely in a bigger population and catches what phase 2 was too small to see. Treating them as the same tier of evidence is the recurring error here.

What does the local patient information leaflet say?

Independent purity testing on this compound is thin compared with the older molecules, simply because fewer members have paid for it. Fewer results means wider uncertainty, not a verdict.

Supply notices are issued nationally. A notice in one member state does not imply availability problems in another, even for the same product.

Watched heart rate on a wearable across twelve weeks because the threads said to. It moved a little and I have no idea whether that means anything.

Strength retention is an imperfect but free longitudinal proxy: it is affected by neural factors and by being in a deficit, so it tracks tissue change loosely rather than exactly.

Combination and monotherapy arms must be read separately. Efficacy and tolerability both differ substantially between them and summaries routinely blur the two.

independent purity data on this compound is thin

Small fix — amylin analogue, not a GLP-1 analogue. The whole mechanism argument changes on that word.

Cross-border prescription recognition exists under EU rules but is conditional and narrower than commonly assumed, with requirements about the prescription’s form and content.

Some lean mass loss accompanies weight loss in any deficit. Resistance training and adequate protein intake are the two interventions with the best evidence for limiting the proportion.

Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.

Same. Naming the country in the first line would fix most of the bad advice on this board.

Are you comparing against a GLP-1 monotherapy result? They are not comparable.

Reimbursed or private?

Small fix — three receptors, not two. GLP-1, GIP and glucagon, and the third one is the reason this compound gets its own board.

not approved anywhere, which is the single most important fact in this board

Reduced appetite makes hitting a protein target a logistics problem rather than a motivation problem, which is why the practical advice here is about timing and food choice rather than willpower.

Combination and monotherapy arms must be read separately. Efficacy and tolerability both differ substantially between them and summaries routinely blur the two.

It is a triple agonist at the GLP-1, GIP and glucagon receptors. The glucagon arm is the genuinely novel component and it is the one with the least human outcome data behind it.

Have you seen the special authorization criteria for your province?

resistance training first, cardio if there is time left

That is an authorisation question and you have answered a reimbursement one. They are decided by different bodies.

keep the prescription and the receipt, both matter for claims

Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.

the energy-expenditure story is mechanistically interesting and clinically unproven

Kept the same programme for a year instead of changing it every six weeks. That was the change that worked.

the exception drug status route exists in several provinces

I would not extrapolate the tolerability profile from the monotherapy arm to the combination.

Disagreeing with this line: that figure is from a combination arm and is being quoted as monotherapy.